# Jan Van den Berghe

> Jan Van den Berghe is a seed investor at Novalis Biotechnology Incubation backing Biotechnology. See 3 investments, check sizes, portfolio and contact…

- Type: Angel Investor
- Fund: [Novalis Biotechnology Incubation](https://shizune.co/investors/profile/novalis-biotechnology-incubation)
- Location: Cranbrook, Canada
- Total investments: 3
- Last investment: Mar 2026
- Lead investor: 67%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/jan-van-den-berghe

Jan Van den Berghe is a seed investor at Novalis Biotechnology Incubation in Cranbrook focused on Biotechnology and Genetics. Jan Van den Berghe is based out of Cranbrook, England and is the Co-Founder of Novalis_Fund. Jan previously worked at OHMX.bio as a Director. Jan Van den Berghe attended INSEAD.

## Contacts

5 contacts available for Jan Van den Berghe: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/jan-van-den-berghe?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Genetics | 1 | 33% |
| Biopharma | 1 | 33% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 33% |
| Switzerland | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alithea Genomics | Alithea Genomics develops molecular biology tools and sequencing-based solutions for large-scale gene expression analysis. The company provides technologies that use RNA barcoding and multiplexing methods to enable the analysis of many RNA samples within a single sequencing experiment. Its products support workflows for RNA sequencing, includinglibrary preparation methods designed for transcriptome profiling and gene expression studies. Alithea Genomics also offers reagents, protocols, and software tools that assist researchers in processing sequencing data and interpreting gene expression results. These technologies are used in academic and industry research settings to study biological processes, disease mechanisms, and cellular responses through transcriptomic analysis. | $3.8M | Seed | Mar 04, 2026 | https://www.alitheagenomics.com/ |
| Alithea Genomics | Alithea Genomics develops molecular biology tools and sequencing-based solutions for large-scale gene expression analysis. The company provides technologies that use RNA barcoding and multiplexing methods to enable the analysis of many RNA samples within a single sequencing experiment. Its products support workflows for RNA sequencing, includinglibrary preparation methods designed for transcriptome profiling and gene expression studies. Alithea Genomics also offers reagents, protocols, and software tools that assist researchers in processing sequencing data and interpreting gene expression results. These technologies are used in academic and industry research settings to study biological processes, disease mechanisms, and cellular responses through transcriptomic analysis. | $3.2M | Seed | Mar 14, 2024 | https://www.alitheagenomics.com/ |
| Carroucell | Carroucell is the microcarrier supplier for cell culture in bioreactor. | $1.5M | Series A | Sep 07, 2022 | https://www.carroucell.com/ |

3 of 3 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [Crédit Agricole Private Bank](https://shizune.co/investors/profile/credit-agricole-aa65) — VC Fund, 1 deal together
- Genku Ventures — VC Fund, 1 deal together
- [Kickfund](https://shizune.co/investors/profile/kickfund) — VC Fund, 1 deal together
- [TechU Ventures](https://shizune.co/investors/profile/techu-ventures) — VC Fund, 1 deal together
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund, 1 deal together

## About Novalis Biotechnology Incubation

VC Fund · Gent, Belgium

Novalis Biotech Incubation seeds biotechnology and life sciences-related companies. We focus on early-stage start-ups and support their evolution by providing funding, sharing our professional and academic connections, and help to shape the business strategy in order to create value for all stakeholders.

4 contacts available at Novalis Biotechnology Incubation.

| Name | Title | Profile |
| --- | --- | --- |
| Jan Berghe | Managing Director & Co-Founder | https://shizune.co/investors/profile/jan-berghe |
| Jan Van den Berghe | Co-Founder | https://shizune.co/investors/profile/jan-van-den-berghe |
| Kjell Mortier | Fund Manager | https://shizune.co/investors/profile/kjell-mortier |
| Wim van Criekinge | Co-Founder & Managing Director | https://shizune.co/investors/profile/wim-van-criekinge-phd |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

## FAQ

### What does Jan Van den Berghe invest in?

Jan Van den Berghe invests primarily in Biotechnology, Genetics and Biopharma startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Jan Van den Berghe?

Public channels for Jan Van den Berghe include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Jan Van den Berghe last invest?

The most recent investment recorded for Jan Van den Berghe closed in Mar 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co